Sebastian Gensior

How outcome-based payment models are forcing royalty investors to rethink fundamental valuation assumptions—and what the early data reveals High-cost gene therapies are ushering in revolutionary one-time treatments—often with price tags in the millions—but they are also forcing a rethink of how payments (and by

Biotech Transactions: November 23-29, 2025 GE HealthCare's $2.3 billion acquisition of Intelerad dominated a shortened Thanksgiving week that still managed to produce meaningful deal flow. Fifteen transactions closed or were announced within the seven-day window, representing over $2.7 billion in disclosed value. November 24

Despite a 73% collapse in venture funding from $15.7B (2021) to $4.2B (2024), China's clinical trial registrations reached unprecedented levels in 2024-2025. The country logged 4,900 clinical trials in 2024—a 13.9% increase year-over-year—and by mid-2025 had nominally surpassed

RA Capital Management, the $12.6 billion biotech-focused investment firm founded in 2001, has aggressively expanded beyond its equity roots into pharmaceutical royalty financing, launching a Structured Capital Solutions platform in September 2024 that positions the firm as an integrated capital provider across the full biopharma lifecycle. This strategic

Company Overview Hanmi Pharm Co. is one of South Korea's leading pharmaceutical companies, distinguished by its heavy investment in novel drug R&D. The company has built an impressive foundation combining domestic market strength with ambitious global aspirations. Key Company Metrics Metric Value Annual Sales ~₩1.5

Introduction: A New Era for Japanese Pharmaceutical Innovation Japan's pharmaceutical landscape is undergoing a profound transformation. No longer dominated solely by household-name giants, the industry now features a vibrant cohort of mid-sized specialty drug makers and cutting-edge biotechnology startups that are punching well above their

A synthetic royalty stream can be viewed not just as an asset purchase but as a complex credit derivative. In essence, when an investor advances cash in exchange for future royalties from a biotech product, they assume a risk profile analogous to a high-yield lender or a seller of

Introduction In today's tough biotech funding climate, many public biotechs have resorted to creative financing combos to stay afloat. Rather than relying on a single source of cash, a distressed company might simultaneously tap a term loan (venture debt), execute a royalty monetization deal, and secure an equity

Biotech and Healthcare Transactions Report: November 17-21, 2025 Abbott's $21 billion Exact Sciences acquisition dominated a busy week that saw $24.6 billion in M&A transactions and $656.5 million in venture financings, signaling renewed dealmaking momentum. The week delivered one mega-deal and four

London has just wrapped up the Jefferies Global Healthcare Conference 2025, now firmly established as Europe’s largest healthcare investment gathering. Over four days (November 17–20, 2025), around 4,500 participants from 50 countries and 950 companies converged on the city. Often dubbed the “J.P. Morgan of Europe,